To Study the Culture Conversion and XDR Suspect of Cat-IV Patients in DOTS Plus Site, S. N. Medical College, Agra
DOI:
https://doi.org/10.21276/4f2hnb07Keywords:
MDR- TB, culture conversion-XDR suspectAbstract
BACKGROUND - Multi-drug resistant tuberculosis (MDR-TB) is an increasing health problem in India. Globally,3.5% of new TB cases and 18% of previously treated cases had MDR/RR-TB.(GLOBAL TUBERCULOSIS REPORT 2018). As per the India TB Report 2018 the estimated incidence of MDRTB/RR in India was approximately 1,47,000.Outcome of MDR patient put on MDR regime is poor due to high cost, long duration of treatment, and various side effect of second line ATT.
MATERIAL & METHOD - Study comprised patients who were diagnosed MDR by culture and DST method from RNTCP accredited lab and initiated CAT–IV treatment in D.R.TB Centre, Department of Tuberculosis & Chest Diseases, S. N. Medical College, Agra. Detailed history and pre clinical evaluation as per guideline were done and at the end of 3rd ,4th,5th and 6th month sputum were send for AFB staining and culture.
RESULT – Out of 109 MDR patient put on CAT-IV, culture conversion at 3rd month occur in 52(47.70%) patients, at 4th month in 58 patients (53.21%), and in 5th month 66 patients (60.55%). Out of 109 MDR TB patients 12 patients (11.01%) were found suspected XDR.
CONCLUSION – MDR TB is major health problem worldwide. Due to less efficacy and more side effect of second line ATT, longer duration of treatment, MDR TB is difficult to treat even with free supply of ATT through DOTS PLUS. Close attention is needed for early diagnosis of MDR TB , and adequate clinically monitoring of during treatment is essential.
Downloads
References
Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven-year DOTS-Plus pilot experience in India: Results, constraints and issues. Int J Tuberc Lung Dis. 2009;13:976–81
Katiyar K, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008;12:139–45.
Prasad R, Verma SK, Sahai S, Kumar S, Jain A. Efficacy and safety of kanamycin, Ethionamide, PAS, and Cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci. 2006;48:183–6.
Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, Myneedu VP. DOTS-Plus for patients with multidrug-resistant tuberculosis in India: Early results after three years. Indian J Chest Dis Allied Sci. 2007;49:75–9
Prasad R, Garg R. XDR-TB: An emerging threat. Chest India. 2007;8:3–4.
Moharil GK, Udwadia ZF. Treating extensively drug resistant tuberculosis (XDR-TB) in India. ERS Annual Congress. 2008;(Session 254)
Jana PK, Das I, Sanyal D, Mandal K. The treatment outcome of multi drug resistant tuberculosis in a teaching hospital. Int Med J. 2009;16:131–6.
Frieden TR, Khatri GR. Tuberculosis, Epidemiology and Control. Vol. 1. New Delhi: WHO, Regional Office for South East Asia; Multi Drug Resistant Tuberculosis; pp. 105–15.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Archives of BioMedical and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors are required to sign and submit the completed “Copyright transfer Form” upon acceptance of publication of the paper. This is determined by a publishing agreement between the author and International Archives of Biomedical and Clinical Research. These rights might include the right to publish, communicate and distribute online. Author(s) retain the copyright of their work. International Archives of Biomedical and Clinical Research supports the need for authors to share, disseminate and maximize the impact of their research.
